Ni Beibei, Li Shi, Liu Yang, Huang Yuqian, Li Zesong
Guangdong Key Laboratory of Systems Biology and Synthetic Biology for Urogenital Tumors, First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, Shenzhen, Guangdong, People's Republic of China.
Shenzhen Key Laboratory of Genitourinary Tumor, First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, Shenzhen, Guangdong, People's Republic of China.
Onco Targets Ther. 2018 Jun 8;11:3377-3384. doi: 10.2147/OTT.S163136. eCollection 2018.
Spleen tyrosine kinase (SYK) was reported to be dysregulated in solid tumors and played an important role in cancer progression. However, the clinical and prognostic values of SYK in solid tumors remain unclear. This meta-analysis investigated the association between SYK expression and clinical outcomes in the patients with solid tumors.
A comprehensive literature search was conducted by screening the online electronic databases of PubMed, Embase, and the China National Knowledge Infrastructure. The hazard ratio (HR) with its corresponding 95% CI was used to explore the prognostic value of SYK.
We analyzed a total of 1,075 patients from 10 studies, which met the criteria for this meta-analysis. Our pooled results demonstrated that a low expression of SYK did not correlate significantly with shorter overall survival (OS; HR=0.64, 95% CI: 0.34-1.21, =0.169) or poorer disease-free survival (HR=0.51, 95% CI: 0.13-2.02, =0.338). However, in a subgroup analysis based on tumor type and test method, under-expression of SYK was positively associated with worse OS in the groups of breast cancer (BC; HR=0.51, 95% CI: 0.32-0.80, =0.003), hepatocellular carcinoma (HCC; HR=0.44, 95% CI: 0.29-0.69, <0.001), methylation (HR=0.39, 95% CI: 0.30-0.51, <0.001), and quantitative reverse transcription polymerase chain reaction (HR=0.24, 95% CI: 0.09-0.65, =0.005).
This meta-analysis demonstrated that under-expression of SYK may serve as a predictive biomarker for poor prognosis in BC and HCC patients. In other solid tumors, the clinical usefulness should be confirmed by large-scale studies.
据报道，脾酪氨酸激酶（SYK）在实体瘤中表达失调，并在癌症进展中起重要作用。然而，SYK在实体瘤中的临床和预后价值仍不清楚。本荟萃分析研究了SYK表达与实体瘤患者临床结局之间的关联。
通过筛选PubMed、Embase和中国知网的在线电子数据库进行全面的文献检索。采用风险比（HR）及其相应的95%置信区间来探讨SYK的预后价值。
我们分析了来自10项研究的总共1075例患者，这些研究符合本荟萃分析的标准。我们的汇总结果表明，SYK低表达与较短的总生存期（OS；HR=0.64，95%置信区间：0.34-1.21，P=0.169）或较差的无病生存期（HR=0.51，95%置信区间：0.13-2.02，P=0.338）无显著相关性。然而，在基于肿瘤类型和检测方法的亚组分析中，SYK低表达与乳腺癌（BC；HR=0.51，95%置信区间：0.32-0.80，P=0.003）、肝细胞癌（HCC；HR=0.44，95%置信区间：0.29-0.69，P<0.001）、甲基化（HR=0.39，95%置信区间：0.30-0.51，P<0.001）和定量逆转录聚合酶链反应（HR=0.24，95%置信区间：0.09-0.65，P=0.005）组中较差的OS呈正相关。
本荟萃分析表明，SYK低表达可能是BC和HCC患者预后不良的预测生物标志物。在其他实体瘤中，其临床实用性应通过大规模研究来证实。
